TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03358017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronate
Description: 4 mg i.v. every 3/4 weeks for 6 months
Study: NCT03610191

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum biomarker tests
Description: Blood was collected at preoperatively, immediately after operation and 24 h after operation in patients from the surgical group but not volunteers. Serum MD2, CysC, DNA methylation marker and SNP mutation sites on CTNNA2 gene were test.

Intervention type: BEHAVIORAL
Intervention: Neuropsychological battery tests
Description: both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.

Intervention type: BEHAVIORAL
Intervention: Neuropsychological battery tests
Description: both surgical patients and volunteers will accept three times of NPB tests. For surgical patients the tested time point are preoperative, one day before discharge and 3 months after surgery. For volunteers the tested time interval would be similar to that of surgical patients.

Intervention type: PROCEDURE
Intervention: Cardiac surgery
Description: patients scheduled for cardiac surgery will accept the surgical procedure.
Study: NCT02134444

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
Study: NCT00226486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multifactorial intervention
Description: Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: No intervention, but ususal care after an accidental fall.
Study: NCT03971565

Intervention type: BIOLOGICAL
Intervention: Blood sample 5 milliliter
Description: The blood of the patients will be collected during their hospitalization of the hematology department participating in the research
Study: NCT00695526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: cranberry
Description: cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
Study: NCT00726635

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive intervention
Description: The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: A one hour conversation with a nurse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: psycho-physiological intervention
Description: The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
Study: NCT03491514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test Granola
Description: 51 g Test Granola

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Granola
Description: 54.1 Control Granola
Study: NCT03877211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: speech audiometry in noise
Description: Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: speech audiometry in noise
Description: Subjects will be asked to repeat lists of words played by speakers in a noisy environment generated by the same speakers. A percentage of correct recognition is calculated for each list.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychophysical tuning curves in forward masking
Description: Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychophysical tuning curves in forward masking
Description: Sounds of variable center frequency are used as maskers, and a tone with a fixed frequency at a fixed level is the target. What is tested here is the level of masker that just masks the target.
Study: NCT03358017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg
Description: 80mg /die os for 6 months
Study: NCT03877211

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrically-evoked Auditory Brainstem Response (EABR)
Description: Channel interaction assessment using eABRs (auditory nerve responses). The method consists of two measurements: 1) eABR measurements with stimulation by a single electrode of the cochlear implant at 70% of the dynamic range (four different electrodes are tested); 2) Measurement of a single eABR with stimulation from all four electrodes at 70% of the dynamic range. A comparison of the eABRs obtained by these two measurements, indicates the electrical and neural interactions between the electrodes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tonal audiometry
Description: Tonal audiometry will be performed with headphones

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auditory canal examination
Description: Otoscopic examination of external auditory canal and eardrum
Study: NCT00406276

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 will be given at a dose of 5mg/day in combination with docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: In combination with RAD001
Study: NCT00940901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sildenafil
Description: sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
Study: NCT02920749

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane group A
Description: In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
Study: NCT04317872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of peri-operative intravenous dexamethasone
Description: 25mg aacidexam is administered during induction followed by 10mg on the ward after 12 hours
Study: NCT02920749

Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane group B
Description: In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
Study: NCT04317872

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of peri-operative intravenous dexamethasone
Description: 10mg aacidexam is administered during induction followed by placebo on the ward after 12 hours
Study: NCT02255006

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Description: Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.~Volunteers undergo FMD measurement and acupuncture like above methods.
Study: NCT02920749

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol group C
Description: In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol group D
Description: In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
Study: NCT02255006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euglucon 5mg
Description: 8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
Study: NCT01142882

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Prevention
Description: Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based Prevention
Description: Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
Study: NCT01960582

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Practice Strategy
Description: Application of a structured case management strategy on housing adaptation cases
Study: NCT01843023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended Release Naltrexone
Description: naltrexone for extended release injectable suspension

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Treatment
Description: Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial Treatment
Description: Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
Study: NCT02255006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Euglucon 5mg
Description: 8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex 200mg
Description: 8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celebrex 200mg
Description: 8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
Study: NCT01843023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
Study: NCT02549001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P-3058 10%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle of P-3058 10%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amorolfine 5%
Study: NCT01915043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education for lymphedema prevention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education for lymphedema prevention
Description: All subjects received a multimodal intervention consist in a multimodal program with an educational approach
Study: NCT03710642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prazosin
Description: Oral prazosin HCl capsules (or placebo) will be administered twice daily, with individualized doses up to a maximum of 4 mg QAM mid-morning and 6 mg at bedtime (QHS), or matching placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo capsule matched to appearance of active drug.
Study: NCT04320355

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soft tissue manual therapy
Description: The intervention is a type of massage.
Study: NCT02240771

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transarterial chemotherapy
Description: Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.~Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.~The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes.
Study: NCT01215253

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine
Description: At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
Study: NCT02240771

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral chemotherapy
Description: Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.~Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD~Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count \& Platelet count would be monitored every 15 days
Study: NCT01079117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevre-Long™
Description: The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Slow release oral morphine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Study: NCT04187456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Single dose (together with midazolam) on Study Day 5 after a high fat, high calorie breakfast.
Study: NCT00104650

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AMG 162 180 mg (SC) q 12 weeks
Description: A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
Study: NCT03358017

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard neoadjuvant cht
Description: Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard neoadjuvant cht
Description: Standard neoadjuvant cht chosen by the investigator and administered according to clinical practice
Study: NCT05216289

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiac
Description: Oral probiotic composed of Lactobacillus acidophilus, Bifidobacterium lactis, vitamins and minerals - Exímia Probiac® (EP), in combination with 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + 2.5% benzoyl peroxide plus 0.1% adapalene (PBA) for topical use.
Study: NCT00104650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Bisphosphonate q 4 weeks
Description: IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
Study: NCT04187456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single dose (alone) on Study Day 1 and single dose (together with savolitinib) on Study Day 5, both after a high fat, high calorie breakfast.